direct thrombin inhibitor


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

direct thrombin inhibitor

Abbreviation: DP
Any medication or substance that interferes with the coagulation of blood by blocking the action of thrombin. Unlike heparins, which are anticoagulants that require the presence of antithrombin to inactivate thrombin, DTIs exert their effects without an intermediary. DTIs can be used to treat and prevent clots in both arteries and veins (although heparin and warfarin are usually preferred for these uses). They are an alternative to heparin in patients with a history of heparin-induced thrombocytopenia. The primary side effect of DTIs is bleeding.
See also: inhibitor
Medical Dictionary, © 2009 Farlex and Partners
Mentioned in ?
References in periodicals archive ?
Wei, "Direct thrombin inhibitors: patents 2002-2012 (review)," Molecular Medicine Reports, vol.
Investigation of Interactions between Thrombin and Ten Phenolic Compounds by Affinity Capillary Electrophoresis and Molecular Docking
Illanes et al., "Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran," Stroke, vol.
The Severity of Intracranial Hemorrhages Measured by Free Hemoglobin in the Brain Depends on the Anticoagulant Class: Experimental Data
Newer oral anticoagulants, such as direct thrombin inhibitors (e.g., dabigatran etexilate) and direct factor Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban), have been developed to overcome these drawbacks, and thereby improve patient care.
Prevention and treatment of venous thromboembolism with new oral anticoagulants: a practical update for clinicians
Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
Novel Oral Anticoagulants: Efficacy, Laboratory Measurement, and Approaches to Emergent Reversal
The direct thrombin inhibitor dabigatran appears to raise the risk of myocardial infarction or acute coronary syndromes, according to a meta-analysis of seven randomized trials.
Dabigatran tied to increase in heart attack risk
(2,5,10,17) A direct thrombin inhibitor (DTI) must be administered for a minimum of 7 days.
Heparin-induced thrombocytopenia (HIT): a case study
Effects of melagatran, a novel direct thrombin inhibitor, in healthy volunteers, following intravenous, subcutaneous and oral administration.
Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?/Atriyal fibrilasyonda ximelagatran ile antitrombotik tedavi: ximelagatran warfarin'e alternatif olabilir mi?
Demographics of Direct Thrombin Inhibitor Use in Pediatric Patients Category Argatroban Bivalirudin (n = 144) (n = 48) Age category, No.
Trends in Parenteral Direct Thrombin Inhibitor Use in Pediatric Patients: Analysis of a Large Administrative Database
According to the company, Angiox is a direct thrombin inhibitor and is indicated in Europe as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.
The Medicines Company renews marketing approval for Angiox in Europe for treating adult patients undergoing percutaneous coronary intervention (PCI)
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Warfarin replacements: good for patients, challenging for laboratories
In addition to the current study of rivaroxaban, they also cited the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY) study, which showed that "dabigatran, a direct thrombin inhibitor, was not inferior to warfarin."
Rivaroxaban rivals warfarin for stroke prevention in A. fib
* Ximelagatran, a direct thrombin inhibitor, appeared to hold promise as an oral anti-coagulant, but was denied FDA approval and eventually withdrawn by its manufacturer when reports of hepatotoxicity and possible myocardial ischemia surfaced.
Treating DVT: answers to 7 key questions: complex recommendations for anticoagulant therapy raise questions for family physicians. Here are the evidence-based answers you need to manage DVT patients successfully

Medical browser ?
Full browser ?